Adjuvant Capital

Adjuvant Capital company information, Employees & Contact Information

Updated June 2026

Quick answer

Adjuvant Capital is a Venture Capital and Private Equity Principals company and founded in 2018. It has approximately 15 employees on record. Contact data was last refreshed in June 2026. Find Adjuvant Capital's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Explore related pages

Related company profiles:

Adjuvant Capital is a life sciences investment firm focused on global health. We make $10-$25 million investments in ambitious companies targeting opportunities in high burden and neglected disease.

Company Details

Employees
15
Founded
2018
Address
New York, Ny 11217, Us
Email
ch****@****tal.com
Industry
Venture Capital And Private Equity Principals
NAICS
Miscellaneous Intermediation
Keywords
A.J. Ventures.
HQ
New York, NY
Looking for a particular Adjuvant Capital employee's phone or email?

Adjuvant Capital Questions

News

Adjuvant Capital Joins $110 Million Series B For Curevo - citybiz

Adjuvant Capital Joins $110 Million Series B For Curevo citybiz

Adjuvant Capital Announces $300 Million Venture Fund Designed to Improve Global Public Health - PR Newswire

Adjuvant Capital Announces $300 Million Venture Fund Designed to Improve Global Public Health PR Newswire

Adjuvant Capital Raises $300 Million Global-Health Venture Fund - The Wall Street Journal

Adjuvant Capital Raises $300 Million Global-Health Venture Fund The Wall Street Journal

Gates, Merck and Novartis-backed Adjuvant Capital raises $300M for neglected diseases - Fierce Biotech

Gates, Merck and Novartis-backed Adjuvant Capital raises $300M for neglected diseases Fierce Biotech

To accelerate innovation, the CDC should ease limits on which labs can handle the coronavirus - statnews.com

To accelerate innovation, the CDC should ease limits on which labs can handle the coronavirus statnews.com

LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections - Business Wire

LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections Business Wire

VitriVax Announces Series A Financing to Further Demonstrate Feasibility of its Thermostable, Single-Dose Vaccine Technology, Aiming to Make Life-Saving Biologics Widely Accessible to Underserved Populations Globally - PR Newswire

VitriVax Announces Series A Financing to Further Demonstrate Feasibility of its Thermostable, Single-Dose Vaccine Technology, Aiming to Make Life-Saving Biologics Widely Accessible to Underserved Populations Globally PR Newswire

African genomics startup 54gene raises $15M led by Adjuvant Capital - TechCrunch

African genomics startup 54gene raises $15M led by Adjuvant Capital TechCrunch

Philippe Dro Joins Adjuvant Capital as Partner - MarketScreener

Philippe Dro Joins Adjuvant Capital as Partner MarketScreener

Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945 - GlobeNewswire

Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945 GlobeNewswire

Top Adjuvant Capital Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant